% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Wang:282521,
author = {X. Wang and A. P. Kutschat and J. Aggrey-Fynn and F. H.
Hamdan and R. P. Graham and A. Q. Wixom and Y. Souto and S.
Ladigan-Badura and J. A. Yonkus and A. M. Abdelrahman and R.
Alva-Ruiz and J. Gaedcke and P. Ströbel and R. L. Kosinsky
and F. Wegwitz and P. Hermann and M. J. Truty and J.
Siveke$^*$ and S. A. Hahn and E. Hessmann and S. A. Johnsen
and Z. Najafova},
title = {{I}dentification of a Δ{N}p63-{D}ependent {B}asal-{L}ike
{A} {S}ubtype-{S}pecific {T}ranscribed {E}nhancer {P}rogram
({B}-{STEP}) in {A}ggressive {P}ancreatic {D}uctal
{A}denocarcinoma.},
journal = {Molecular cancer research},
volume = {21},
number = {9},
issn = {1541-7786},
address = {Philadelphia, Pa.},
publisher = {AACR},
reportid = {DKFZ-2023-01810},
pages = {881 - 891},
year = {2023},
abstract = {A major hurdle to the application of precision oncology in
pancreatic cancer is the lack of molecular stratification
approaches and targeted therapy for defined molecular
subtypes. In this work, we sought to gain further insight
and identify molecular and epigenetic signatures of the
Basal-like A pancreatic ductal adenocarcinoma (PDAC)
subgroup that can be applied to clinical samples for patient
stratification and/or therapy monitoring. We generated and
integrated global gene expression and epigenome mapping data
from patient-derived xenograft models to identify
subtype-specific enhancer regions that were validated in
patient-derived samples. In addition, complementary nascent
transcription and chromatin topology (HiChIP) analyses
revealed a Basal-like A subtype-specific transcribed
enhancer program in PDAC characterized by enhancer RNA
(eRNA) production that is associated with more frequent
chromatin interactions and subtype-specific gene activation.
Importantly, we successfully confirmed the validity of eRNA
detection as a possible histologic approach for PDAC patient
stratification by performing RNA-ISH analyses for
subtype-specific eRNAs on pathologic tissue samples. Thus,
this study provides proof-of-concept that subtype-specific
epigenetic changes relevant for PDAC progression can be
detected at a single-cell level in complex, heterogeneous,
primary tumor material.Subtype-specific enhancer activity
analysis via detection of eRNAs on a single-cell level in
patient material can be used as a potential tool for
treatment stratification.},
keywords = {Humans / Precision Medicine / Pancreatic Neoplasms:
pathology / Carcinoma, Pancreatic Ductal: pathology / RNA /
Gene Expression Regulation, Neoplastic / RNA (NLM
Chemicals)},
cin = {ED01},
ddc = {610},
cid = {I:(DE-He78)ED01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37279184},
doi = {10.1158/1541-7786.MCR-22-0916},
url = {https://inrepo02.dkfz.de/record/282521},
}